Optimistic Growth Outlook for Maravai Lifesciences Holdings Despite Challenges

Wells Fargo analyst Brandon Couillard has maintained their bullish stance on MRVI stock, giving a Buy rating yesterday.

Brandon Couillard has given his Buy rating due to a combination of factors that highlight Maravai Lifesciences Holdings’ potential for growth. The company demonstrated a solid performance in the first quarter of 2025, with revenue exceeding expectations and showing sequential growth in its base Nucleic Acid Production business for the first time since the fourth quarter of 2023. This indicates a positive trend in the company’s core operations.
Furthermore, the stability and expansion of Maravai’s mRNA and gene editing program pipeline suggest sustained investment and development opportunities. The reaffirmation of the full-year revenue guidance and expectations of modest growth in the second half of the year, supported by strategic acquisitions, also contribute to the optimistic outlook. Despite challenges such as lower-than-expected EBITDA and margin issues, the focus on the base business and the potential for future revenue growth underpin the Buy rating.

In another report released yesterday, Craig-Hallum also maintained a Buy rating on the stock with a $10.00 price target.